Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous GCC-targeting CAR T Cells GCC19CART

A preparation of autologous T lymphocytes that are genetically engineered to express a chimeric antigen receptor (CAR) targeting the enterocyte differentiation antigen guanylyl cyclase C (GUCY2C) that are activated with CAR T cells specific for the CD19 antigen, and coupled to as of yet not fully elucidated signaling domains, with potential immunostimulating and antineoplastic activities. Upon intravenous administration, the autologous GCC-targeting CAR T cells GCC19CART are directed to, specifically bind to, activate, proliferate and release cytokines that promote killing of GCC-expressing tumor cells. GCC is overexpressed in various tumor cell types. The activation of the GCC-targeting T cells by activated CD19 CAR that secrete cytokines, enhances CAR T-cell activation and proliferation, and may increase the T-cell-mediated killing of GCC-expressing tumor cells.
Synonym:anti-GCC autologous CAR T cells GCC19CART
GCC-targeted coupled CAR T cells GCC19CART
Code name:GCC19 CART
GCC19-CART
GCC19CART
Search NCI's Drug Dictionary